{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:18:41Z","timestamp":1789996721938,"version":"4.0.1"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1097\/wco.0000000000000336","type":"journal-article","created":{"date-parts":[[2016,4,19]],"date-time":"2016-04-19T17:14:08Z","timestamp":1461086048000},"page":"254-262","source":"Crossref","is-referenced-by-count":57,"title":["Precision medicine in multiple sclerosis"],"prefix":"10.1097","volume":"29","author":[{"given":"Manuel","family":"Comabella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Sastre-Garriga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210206","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S1474-4422(13)70233-3","article-title":"Body fluid biomarkers in multiple sclerosis","volume":"13","author":"Comabella","year":"2014","journal-title":"Lancet Neurol"},{"key":"R2-9-20210206","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrneurol.2015.106","article-title":"Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process","volume":"11","author":"Rovira","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"R5-9-20210206","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00415-015-7668-9","article-title":"Criteria improving multiple sclerosis diagnosis at the first MRI","volume":"262","author":"Caucheteux","year":"2015","journal-title":"J Neurol"},{"key":"R6-9-20210206","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1212\/WNL.0000000000001367","article-title":"MRI characteristics of neuromyelitis optica spectrum disorder: an international update","volume":"84","author":"Kim","year":"2015","journal-title":"Neurology"},{"key":"R7-9-20210206","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol"},{"key":"R8-9-20210206","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines","volume":"15","author":"Filippi","year":"2016","journal-title":"Lancet Neurol"},{"key":"R9-9-20210206","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","article-title":"Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis: establishing disease prognosis and monitoring patients","volume":"11","author":"Wattjes","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"R10-9-20210206","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1212\/WNL.0000000000001281","article-title":"Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis","volume":"84","author":"Radue","year":"2015","journal-title":"Neurology"},{"key":"R11-9-20210206","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining high, medium and low impact prognostic factors for developing multiple sclerosis","volume":"138","author":"Tintore","year":"2015","journal-title":"Brain"},{"key":"R12-9-20210206","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1177\/1352458514568827","article-title":"Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study","volume":"21","author":"Kuhle","year":"2015","journal-title":"Mult Scler"},{"key":"R13-9-20210206","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1212\/WNL.0000000000001587","article-title":"Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis","volume":"85","author":"Absinta","year":"2015","journal-title":"Neurology"},{"key":"R14-9-20210206","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1212\/WNL.0000000000001286","article-title":"Investigation of leptomeningeal enhancement in MS: a postcontrast FLAIR MRI study","volume":"84","author":"Eisele","year":"2015","journal-title":"Neurology"},{"key":"R15-9-20210206","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"R16-9-20210206","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1212\/NXI.0000000000000132","article-title":"Predictive value of early brain atrophy on response in patients treated with interferon \u03b2","volume":"2","author":"P\u00e9rez-Miralles","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R17-9-20210206","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/1352458515569099","article-title":"Fingolimod effect on brain volume loss independently contributes to its effect on disability","volume":"21","author":"Sormani","year":"2015","journal-title":"Mult Scler"},{"key":"R19-9-20210206","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/brain\/awv017","article-title":"Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes","volume":"138","author":"Cant\u00f3","year":"2015","journal-title":"Brain"},{"key":"R20-9-20210206","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/brain\/awq035","article-title":"Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis","volume":"133","author":"Comabella","year":"2010","journal-title":"Brain"},{"key":"R21-9-20210206","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1177\/1352458514561906","article-title":"Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis","volume":"21","author":"Hinsinger","year":"2015","journal-title":"Mult Scler"},{"key":"R22-9-20210206","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1177\/1352458515574148","article-title":"Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis","volume":"21","author":"Modvig","year":"2015","journal-title":"Mult Scler"},{"key":"R23-9-20210206","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/1352458514549397","article-title":"Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis","volume":"21","author":"Mart\u00ednez","year":"2015","journal-title":"Mult Scler"},{"key":"R25-9-20210206","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/1352458514546789","article-title":"Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis","volume":"21","author":"Tortorella","year":"2015","journal-title":"Mult Scler"},{"key":"R26-9-20210206","first-page":"126","article-title":"Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome","volume":"87","author":"Disanto","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R29-9-20210206","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jneuroim.2015.04.011","article-title":"Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis","volume":"283","author":"Ferraro","year":"2015","journal-title":"J Neuroimmunol"},{"key":"R30-9-20210206","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12974-015-0269-9","article-title":"Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis","volume":"12","author":"Malhotra","year":"2015","journal-title":"J Neuroinflammation"},{"key":"R31-9-20210206","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12974-015-0418-1","article-title":"Next-generation sequencing identifies altered whole blood microRNAs in neuromyelitis optica spectrum disorder which may permit discrimination from multiple sclerosis","volume":"12","author":"Keller","year":"2015","journal-title":"J Neuroinflammation"},{"key":"R32-9-20210206","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbi.2015.07.016","article-title":"Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms","volume":"51","author":"Aeinehband","year":"2016","journal-title":"Brain Behav Immun"},{"key":"R33-9-20210206","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jprot.2015.02.018","article-title":"Serum proteomics in multiple sclerosis disease progression","volume":"118","author":"Tremlett","year":"2015","journal-title":"J Proteomics"},{"key":"R34-9-20210206","doi-asserted-by":"crossref","first-page":"e0129291","DOI":"10.1371\/journal.pone.0129291","article-title":"Vitamin D binding protein isoforms and apolipoprotein e in cerebrospinal fluid as prognostic biomarkers of multiple sclerosis","volume":"10","author":"Perga","year":"2015","journal-title":"PLoS One"},{"key":"R35-9-20210206","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1002\/pmic.201400142","article-title":"Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis","volume":"15","author":"Kroksveen","year":"2015","journal-title":"Proteomics"},{"key":"R36-9-20210206","doi-asserted-by":"crossref","first-page":"e0143393","DOI":"10.1371\/journal.pone.0143393","article-title":"Changes in blood B cell-activating factor (BAFF) levels in multiple sclerosis: a sign of treatment outcome","volume":"10","author":"Kannel","year":"2015","journal-title":"PLoS One"},{"key":"R37-9-20210206","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","article-title":"Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"13","author":"Kappos","year":"2014","journal-title":"Lancet Neurol"},{"key":"R38-9-20210206","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1136\/jnnp-2014-309827","article-title":"The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up","volume":"86","author":"Petzold","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R39-9-20210206","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ana.24429","article-title":"A pharmacogenetic study implicates SLC9A9 in multiple sclerosis disease activity","volume":"78","author":"Esposito","year":"2015","journal-title":"Ann Neurol"},{"key":"R40-9-20210206","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/brain\/awu388","article-title":"NLRP3 inflammasome is associated with the response to IFN-\u03b2 in patients with multiple sclerosis","volume":"138","author":"Malhotra","year":"2015","journal-title":"Brain"},{"key":"R41-9-20210206","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1177\/1352458514555786","article-title":"Prognostic biomarkers of IFNb therapy in multiple sclerosis patients","volume":"21","author":"Baranzini","year":"2015","journal-title":"Mult Scler"},{"key":"R42-9-20210206","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1371\/journal.pbio.0030002","article-title":"Transcription-based prediction of response to IFNbeta using supervised computational methods","volume":"3","author":"Baranzini","year":"2005","journal-title":"PLoS Biol"},{"key":"R43-9-20210206","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.yexmp.2015.09.007","article-title":"RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis","volume":"99","author":"Kruszewski","year":"2015","journal-title":"Exp Mol Pathol"},{"key":"R44-9-20210206","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0000000000001454","article-title":"Hematopoietic mobilization: potential biomarker of response to natalizumab in multiple sclerosis","volume":"84","author":"Mattoscio","year":"2015","journal-title":"Neurology"},{"key":"R46-9-20210206","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.jns.2015.08.1537","article-title":"Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis","volume":"358","author":"Novakova","year":"2015","journal-title":"J Neurol Sci"},{"key":"R47-9-20210206","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/ana.24345","article-title":"Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab","volume":"77","author":"Villar","year":"2015","journal-title":"Ann Neurol"},{"key":"R49-9-20210206","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","article-title":"L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients","volume":"81","author":"Schwab","year":"2013","journal-title":"Neurology"},{"key":"R50-9-20210206","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.0000000000002314","article-title":"CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients","volume":"86","author":"Lieberman","year":"2016","journal-title":"Neurology"},{"key":"R51-9-20210206","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1212\/WNL.0000000000001491","article-title":"Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis","volume":"84","author":"Kuhle","year":"2015","journal-title":"Neurology"}],"container-title":["Current Opinion in Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WCO.0000000000000336","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:56:25Z","timestamp":1620978985000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019052-201606000-00009"}},"subtitle":["biomarkers for diagnosis, prognosis, and treatment response"],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/wco.0000000000000336","relation":{},"ISSN":["1350-7540"],"issn-type":[{"value":"1350-7540","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}